Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Breaking Down the Data in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg

June 6th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 6th 2023

The addition of sintilimab to chemoradiotherapy demonstrated a significant reduction in the risk of disease recurrence or death, distant metastasis and locoregional recurrence compared with chemoradiotherapy alone as frontline therapy in patients with locally advanced nasopharyngeal carcinoma, according to findings from the phase 3 CONTINUUM trial.

Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC

June 5th 2023

Nivolumab plus ipilimumab and chemotherapy continued to show durable benefit at 4 years compared with chemotherapy alone as first-line therapy in patients with advanced non–small cell lung cancer, particularly in the PD-L1–negative and squamous populations.

Gaining Ground in Gynecologic and Hematologic Cancers at ASCO 2023: Drs Herrera, Westin, and Jabbour

June 5th 2023

Tovorafenib Presents Opportunity for Tumor Reduction in Pediatric Low-Grade Glioma

June 4th 2023

Treatment with tovorafenib elicited encouraging and fast onset responses in heavily pretreated pediatric patients with low-grade glioma regardless of response assessment criteria, according to data from the phase 2 FIREFLY-1 trial that were presented at the 2023 ASCO Annual Meeting.

Looking at the Latest Data in Lung Cancer at ASCO 2023: Dr Naidoo

June 4th 2023

Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma

June 4th 2023

Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.

HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast Cancer

June 1st 2023

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

May 30th 2023

The FDA has granted priority review to repotrectinib for the treatment of patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer.

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

May 26th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based chemotherapy for patients with resectable non–small cell lung cancer at high risk of recurrence and tumor cell PD-L1 expression of at least 1%.

Luspatercept Nearly Doubles Likelihood of Transfusion Independence in Lower-Risk MDS

May 25th 2023

Luspatercept-aamt led to a higher rate of sustained transfusion independence compared with erythropoiesis stimulating agents in patients with ESA-naïve, lower-risk myelodysplastic syndrome.

NCCN Guidelines Endorse FES PET for Workup of Recurrent/Metastatic ER+ Breast Cancer

May 25th 2023

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.

NCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia Vera

May 24th 2023

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.

FDA Grants Orphan Drug Designation to Mitazalimab in Pancreatic Cancer

May 22nd 2023

The FDA has granted an orphan drug designation to mitazalimab for use as a potential therapeutic option in patients with pancreatic cancer.

FDA Grants Orphan Drug Designation to Rucosopasem for Pancreatic Cancer

May 18th 2023

The FDA has granted an orphan drug designation to rucosopasem manganese for the treatment of patients with pancreatic cancer.

ECLIPSE PV Trial Begins Ropeginterferon Alfa-2b Dosing in Polycythemia Vera

May 15th 2023

The first patients have been dosed in the phase 3b ECLIPSE PV trial, which is evaluating an accelerated dosing schedule of ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

Neoadjuvant Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Shows High pCR Rate in Early HER2+ Breast Cancer

May 12th 2023

Preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab led to improved rates of pathologic complete response and decreased residual cancer burden compared with trastuzumab, pertuzumab, and chemotherapy alone in patients with early-stage HER2-positive breast cancer, according to findings from the randomized phase 2 ATHENE trial.

PYX-201 Receives Orphan Drug Designation From the FDA in Pancreatic Cancer

May 12th 2023

The FDA has granted an orphan drug designation to PYX-201 for the treatment of patients with pancreatic cancer.

Toxicity Profile With Trastuzumab Deruxtecan Proves Consistent, Manageable in HER2-Low Metastatic Breast Cancer

May 11th 2023

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.

Mirvetuximab Soravtansine Improves PFS, OS in FRα+ Platinum-Resistant Ovarian Cancer

May 3rd 2023

Mirvetuximab soravtansine-gynx led to a clinically meaningful and statistically significant improvement in progression-free survival, overall survival, and objective response rate vs single-agent chemotherapy in patients with platinum-resistant ovarian cancer whose tumors express high levels of folate receptor alpha, according to topline findings from the phase 3 MIRASOL trial.